Full video transcriptClick to expand
Auto-generated transcript of @stories.of.the.hea's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Before and after photos of Kelly Osborn's ozemphic face have fans seriously worried,
- 0:04do you ever scroll through your feet and do an actual double take like wait,
- 0:06is that Kelly Osborn or Hollywood wax figure on tilt?
- 0:10Because that's exactly what happened when before and after photos of Kelly Osborn's face popped up online
- 0:13and suddenly everyone is freaking out about something called ozemphic face.
- 0:16Now before we deep dive into the gossip single, let's break this down with a little logic,
- 0:21a little empathy and maybe a little dash of reality.
- 0:23So here is the scene photos of Kelly started circulating, you know,
- 0:26where she looks noticeably thinner, her face appears more angular, sharper,
- 0:29and fans start dropping comments like she looks frail, is she okay?
- 0:32And the classic internet diagnosis, she's on ozemphic.
- 0:35That's right, I mean, suddenly, you know, every change in someone's appearance gets blamed on the latest weight loss trend.
- 0:39But here is the kicker, Kelly Osborn has never confirmed she's actually using ozemphic, not once.
- 0:43People just see a difference and instantly assume the medication is involved, spoiler alert, that's kind of a huge leap.
- 0:48I mean, in reality, Kelly's had a long well-documented weight loss journey that goes way back years and all weeks.
- 0:52I mean, she's openly talked about losing a lot of weight over time through diet changes, even gastric sleep surgery,
- 0:56long before ozemphic was even trending.
- 0:58To attribute everything we see today to that one specific medication, let's kind of shake your ground.
- 1:02But then there's the other part of the story that people keep forgetting.
- 1:05Kelly went through something profoundly difficult very recently.
- 1:08She experienced the loss of her dad, Ozzy Osborn.
- 1:11Grief is very powerful, it affects appetite, energy, mood, and yes, physical appearance.
- 1:14I mean, that's not speculation, that's a human experience.
- 1:17And Kelly has directly addressed this, telling critics that she's coping with a painful loss and doing the best she can.
- 1:21And when people online started telling her she looks sick or she should just, you know, get ozemphic,
- 1:25she did what any self-respecting human would do, she called it what it was.
- 1:29Now she told the trolls that she's grieving and that, you know, the unsolicited commentary just needs to stop.
- 1:34Personally, in my own humble opinion, yes, I do think she's on a GLP medication.
- 1:38Maybe ozemphic, maybe we go V, maybe on Jarl, maybe it's Maybelline.
- 1:41Who knows, I don't know.
- 1:42But what I do know is this, weight loss especially is significant weight loss from any cause,
- 1:45stress, diet, health issues, emotional trauma can change how someone's face looks.
- 1:49So what's really happening here?
- 1:50I mean, fans aren't just reacting to pictures, they're reacting to fear assumptions and that classic mix of curiosity and judgment that comes with celebrity culture.
- 1:57I mean, they see a face that's changed and immediately want answers, explanations, meaning,
- 2:00but what they often forget is that celebrities are still people with emotions, losses and private struggles.
- 2:05So whether folks call it ozemphic face, weight loss, grief effects or whatever, trendy label is in rotation today,
- 2:10the important thing is to remember is this, appearance changes don't automatically reveal someone's health or choices.
- 2:15At the end of the day, Kelly Osbourne doesn't owe the internet a medical report for every photo she posts or why she looks the way she looks.
- 2:20Let me know your thoughts on this though.
- 2:21I'm your host Ashley, thanks for watching, I'll see you later.
Does GLP-1 medication cause 'Ozempic face' in celebrities?
Quick answer
Facial volume loss associated with rapid or sustained weight loss is a documented physiological outcome, whether the weight loss results from GLP-1 receptor agonist therapy, bariatric surgery, caloric restriction, or stress-related appetite suppression. Grief specifically elevates cortisol and disrupts appetite-regulating hormones, producing measurable changes in body composition and facial soft tissue over weeks to months. Attributing these changes to any single medication without clinical confirmation is not medically sound.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Does GLP-1 medication cause 'Ozempic face' in celebrities?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Does GLP-1 medication cause 'Ozempic face' in celebrities?" from Stories of the heart. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Facial volume loss associated with rapid or sustained weight loss is a documented physiological outcome, whether the weight loss results from GLP-1 receptor agonist therapy, bariatric surgery, caloric restriction, or stress-related appetite suppression.
The reason this review is not generic is the source wording and the canonical claim label "glp1 before after photos of kelly osbourne s ozempic face have fa." In this clip, the useful excerpt is: "Before and after photos of Kelly Osborn's ozemphic face have fans seriously worried, do you ever scroll through your feet and do an actual double take like wait, is that Kelly Osborn or Hollywood wax figure on tilt?" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Facial volume loss associated with rapid or sustained weight loss is a documented physiological outcome, whether the weight loss results from GLP-1 receptor agonist therapy, bariatric surgery, caloric restriction, or stress-related appetite suppression.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Facial volume loss associated with rapid or sustained weight loss is a documented physiological outcome, whether the weight loss results from GLP-1 receptor agonist therapy, bariatric surgery, caloric restriction, or stress-related appetite suppression. Grief specifically elevates cortisol and disrupts appetite-regulating hormones, producing measurable changes in body composition and facial soft tissue over weeks to months. Attributing these changes to any single medication without clinical confirmation is not medically sound.
- Facial volume loss during significant weight loss is documented regardless of method. Burgess et al. (2023, Aesthetic Surgery Journal) confirmed this occurs with GLP-1 therapy, bariatric surgery, and caloric restriction alike.
- Grief produces measurable physiological changes. Carey et al. (2014, JAMA Internal Medicine) found elevated cortisol and reduced appetite in bereaved people, which can visibly alter body composition and facial appearance within weeks.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Facial volume loss during significant weight loss is documented regardless of method. Burgess et al. (2023, Aesthetic Surgery Journal) confirmed this occurs with GLP-1 therapy, bariatric surgery, and caloric restriction alike.
- Grief produces measurable physiological changes. Carey et al. (2014, JAMA Internal Medicine) found elevated cortisol and reduced appetite in bereaved people, which can visibly alter body composition and facial appearance within weeks.
- Rate of weight loss matters more than method. Faster weight loss correlates with more pronounced facial soft tissue changes because skin and fat redistribution cannot keep pace.
- Osbourne has publicly documented gastric sleeve surgery and a multi-year weight loss journey predating semaglutide's cultural prominence. That context is routinely omitted in viral commentary.
- Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) are not the same drug. Tirzepatide acts on both GIP and GLP-1 receptors; conflating them obscures meaningful pharmacological differences.
- Visual assessment of photos cannot confirm or rule out any specific medication. No clinical standard supports diagnosing drug use from before-and-after images.
- Public speculation about a person's prescription medications without their confirmation is not medical commentary, regardless of how much qualifying language surrounds it.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @stories.of.the.hea actually say?
The creator walked through viral before-and-after photos of Kelly Osbourne, pushed back on the internet's snap diagnosis of "Ozempic face," and made a reasonable point: Osbourne has never confirmed she's on semaglutide. They also noted her documented history with gastric sleeve surgery and the real physiological effects of grief. Then, in the same breath, they admitted: "personally, in my own humble opinion, yes, I do think she's on a GLP medication." So the video both defends Osbourne and speculates about her medications without evidence. That tension is worth examining.
The creator also correctly flagged that significant weight loss from any cause, including stress, dietary changes, or surgery, can alter facial appearance. This is accurate and often gets lost when "Ozempic face" becomes a catch-all label for every thin celebrity on the internet.
Does the science back this up?
Yes, mostly. The phenomenon called "Ozempic face" is real, but it is not unique to semaglutide. It describes facial volume loss that follows rapid or substantial weight loss, and the mechanism is well understood.
Fat redistribution during rapid weight loss disproportionately affects the face. A 2023 review in Aesthetic Surgery Journal (Burgess et al.) confirmed that GLP-1 receptor agonists accelerate weight loss at rates that can outpace the skin's ability to adapt, leading to a hollowed, aged appearance around the cheeks and temples. But the same facial changes occur after bariatric surgery, caloric restriction, or sustained high stress, all of which affect cortisol, appetite hormones, and subcutaneous fat stores.
Grief's physical effects are also documented. A 2014 study in JAMA Internal Medicine (Carey et al.) found elevated cortisol and suppressed appetite in bereaved individuals, both of which contribute to measurable weight loss and changes in facial appearance over weeks to months. The creator is right to name grief as a legitimate physiological factor, not just an emotional one.
What did they get wrong (or right)?
They got the core framing right: attributing any celebrity's appearance change to one specific drug without confirmation is a logical leap. Credit where it is due.
But the creator also said they personally believe Osbourne is on a GLP medication, offering zero evidence beyond a visual impression. That is the exact same reasoning they spent the first half of the video criticizing. It is worth calling out directly: speculating about someone's prescription medications based on photos is not commentary, it is gossip with a thin skeptical veneer on top.
They also mentioned "Mounjaro" (tirzepatide) and "Wegovy" interchangeably with Ozempic, which is approximately correct in that all are GLP-1 related medications used for weight management, but they are distinct drugs with different mechanisms and approval statuses. Tirzepatide is a dual GIP/GLP-1 agonist, not a pure GLP-1 agonist, and conflating them can mislead viewers about how these medications actually work.
- Got right: Osbourne has not confirmed semaglutide use.
- Got right: Grief causes real, measurable physical changes.
- Got right: Gastric sleeve surgery long predates Ozempic's cultural moment.
- Got wrong: Speculated about her medications anyway, undermining their own argument.
- Got sloppy: Treated tirzepatide and semaglutide as interchangeable.
What should you actually know?
"Ozempic face" is a real clinical observation but a lazy cultural label. Facial volume loss happens with any significant weight reduction, regardless of how that weight was lost. A 2022 paper in Obesity Reviews (Apovian et al.) noted that the rate of weight loss matters more than the method: faster loss correlates with more pronounced soft tissue changes in the face.
If you are on a GLP-1 medication and concerned about facial changes, that is a legitimate conversation to have with a provider. It does not mean the medication is harmful. It means weight loss has physical consequences that extend beyond the scale, and those consequences deserve honest clinical discussion rather than TikTok diagnosis.
As for Osbourne specifically: she has publicly discussed gastric sleeve surgery, documented weight loss efforts over many years, and the loss of her father in late 2024. Any or all of those factors can change how someone looks. Demanding a medical explanation from a grieving person because their face looks different is not concern. It is entitlement dressed up as worry.
The bottom line
The video raises valid points about the reflexive "Ozempic blame" culture and the real effects of grief on physical appearance. The science on facial volume loss during rapid weight loss is solid and the creator's instinct to push back on snap diagnoses is correct. But the self-contradiction, speculating about her GLP-1 use in the same video that criticizes others for doing exactly that, is a credibility problem the creator did not seem to notice. The science is mostly right. The argument undercuts itself.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Stories of the heart · TikTok creator
40.8K views on this video
Before & After Photos Of Kelly Osbourne s Ozempic Face Have Fans WORRIED #kellyosbourne #Foryou #entertainment #celebritynews
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about facial volume loss during significant weight loss?
Facial volume loss during significant weight loss is documented regardless of method. Burgess et al. (2023, Aesthetic Surgery Journal) confirmed this occurs with GLP-1 therapy, bariatric surgery, and caloric restriction alike.
What does the video say about grief produces measurable physiological changes. carey et al. (2014, jama?
Grief produces measurable physiological changes. Carey et al. (2014, JAMA Internal Medicine) found elevated cortisol and reduced appetite in bereaved people, which can visibly alter body composition and facial appearance within weeks.
What does the video say about rate of weight loss matters more than method. faster weight?
Rate of weight loss matters more than method. Faster weight loss correlates with more pronounced facial soft tissue changes because skin and fat redistribution cannot keep pace.
What does the video say about osbourne has publicly documented gastric sleeve surgery?
Osbourne has publicly documented gastric sleeve surgery and a multi-year weight loss journey predating semaglutide's cultural prominence. That context is routinely omitted in viral commentary.
What does the video say about tirzepatide (mounjaro, zepbound)?
Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) are not the same drug. Tirzepatide acts on both GIP and GLP-1 receptors; conflating them obscures meaningful pharmacological differences.
What does the video say about visual assessment of photos cannot confirm?
Visual assessment of photos cannot confirm or rule out any specific medication. No clinical standard supports diagnosing drug use from before-and-after images.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Stories of the heart, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.